LLB BSc - Telix Pharmaceuticals Group Secretary
| TLX Stock | 25.74 0.80 3.21% |
Executive
LLB BSc is Group Secretary of Telix Pharmaceuticals
| Address | 55 Flemington Road, North Melbourne, VIC, Australia, 3051 |
| Phone | 61 3 9093 3855 |
| Web | https://telixpharma.com |
Telix Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.0797 % which means that it generated a profit of $0.0797 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2049 %, meaning that it generated $0.2049 on every $100 dollars invested by stockholders. Telix Pharmaceuticals' management efficiency ratios could be used to measure how well Telix Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Telix Pharmaceuticals' Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 418.2 M in 2024, whereas Non Current Liabilities Total is likely to drop slightly above 48.8 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Karen OFlynn | Commonwealth Bank | N/A | |
| Sweta Mehra | Australia and New | N/A | |
| Kevin Corbally | ANZ Group Holdings | 51 | |
| Yeekei Chan | Australia and New | N/A | |
| Clare Morgan | ANZ Group Holdings | 46 | |
| Clare Morgan | Australia and New | 46 | |
| Clare Morgan | ANZ Group Holdings | 46 | |
| Phoebe OSullivan | Australia and New | N/A | |
| Rodrigo Castillo | Commonwealth Bank of | N/A | |
| Nigel BCom | Commonwealth Bank | 62 | |
| Elisa Clements | Australia and New | N/A | |
| Farhan Faruqui | ANZ Group Holdings | 59 | |
| Khoon Goh | Australia and New | N/A | |
| Karen OFlynn | Commonwealth Bank of | N/A | |
| Nigel BCom | Commonwealth Bank of | 62 | |
| Mark Whelan | ANZ Group Holdings | 64 | |
| Antony Strong | ANZ Group Holdings | 52 | |
| Kevin Corbally | ANZ Group Holdings | 51 | |
| Gerard Florian | ANZ Group Holdings | 58 | |
| Truett Tate | Australia and New | 74 | |
| Adam Boyton | Australia and New | N/A | |
Management Performance
| Return On Equity | 0.2 | ||||
| Return On Asset | 0.0797 |
Telix Pharmaceuticals Leadership Team
Elected by the shareholders, the Telix Pharmaceuticals' board of directors comprises two types of representatives: Telix Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Telix. The board's role is to monitor Telix Pharmaceuticals' management team and ensure that shareholders' interests are well served. Telix Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Telix Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Meredith Crowe, Interim Culture | ||
| BSc BSc, Chief Scientist | ||
| Christian Davis, EMEA Marketing | ||
| Richard MBA, Chief Therapeutics | ||
| Lena LLB, General Counsel | ||
| Darren Patti, Group Officer | ||
| Kyahn Williamson, Sr Relations | ||
| Craig Ulrick, Chief Officer | ||
| MBA MD, Group Officer | ||
| Lena MoranAdams, G Counsel | ||
| Michelle Hickey, Senior Operations | ||
| LLB BSc, Group Secretary | ||
| Thomas Fromm, Vice Sales | ||
| Ted Stephens, Vice Marketing | ||
| Andreas MD, Chief Director | ||
| Amanda Griffin, Communications Mang | ||
| Shintaro BSc, President Japan | ||
| BEng DPhil, Group CoFounder | ||
| Meredith BDES, Senior Culture | ||
| Kyahn BA, Senior Relations | ||
| BBus FCPA, Group Officer | ||
| AGIA ACG, Risk Governance | ||
| Mary Jessel, Senior Affairs |
Telix Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Telix Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.2 | ||||
| Return On Asset | 0.0797 | ||||
| Profit Margin | 0.08 % | ||||
| Operating Margin | 0.09 % | ||||
| Current Valuation | 8.25 B | ||||
| Shares Outstanding | 334.72 M | ||||
| Shares Owned By Insiders | 41.42 % | ||||
| Shares Owned By Institutions | 17.91 % | ||||
| Price To Book | 20.66 X | ||||
| Price To Sales | 13.23 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Telix Stock Analysis
When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.